SEC Form 4 · accession 0001209191-17-062224
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew G Long
Officer — Chief Financial Officer
Period of report
Nov 17, 2017
Accepted (ET)
Nov 21, 2017 · 9:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.37 | Nov 17, 2017 | A | 15,000 | A | — | Nov 16, 2027 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option shall vest in 36 equal monthly installments until fully vested and exercisable on November 17, 2020.